CANF vs. LPTX, UBX, UPXI, MBRX, NRSN, INAB, FLGC, BCDA, GOVX, and EQ
Should you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include Leap Therapeutics (LPTX), Unity Biotechnology (UBX), Upexi (UPXI), Moleculin Biotech (MBRX), NeuroSense Therapeutics (NRSN), IN8bio (INAB), Flora Growth (FLGC), BioCardia (BCDA), GeoVax Labs (GOVX), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry.
Can-Fite BioPharma vs.
Can-Fite BioPharma (NYSE:CANF) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation, institutional ownership and community ranking.
Can-Fite BioPharma has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.17, meaning that its share price is 117% less volatile than the S&P 500.
Leap Therapeutics received 284 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 68.37% of users gave Leap Therapeutics an outperform vote while only 12.20% of users gave Can-Fite BioPharma an outperform vote.
21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 5.4% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Can-Fite BioPharma currently has a consensus target price of $14.00, suggesting a potential upside of 1,251.35%. Leap Therapeutics has a consensus target price of $4.92, suggesting a potential upside of 1,260.45%. Given Leap Therapeutics' higher possible upside, analysts clearly believe Leap Therapeutics is more favorable than Can-Fite BioPharma.
Can-Fite BioPharma's return on equity of 0.00% beat Leap Therapeutics' return on equity.
Can-Fite BioPharma has higher revenue and earnings than Leap Therapeutics. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Leap Therapeutics had 7 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 7 mentions for Leap Therapeutics and 0 mentions for Can-Fite BioPharma. Leap Therapeutics' average media sentiment score of 1.01 beat Can-Fite BioPharma's score of 0.00 indicating that Leap Therapeutics is being referred to more favorably in the news media.
Summary
Leap Therapeutics beats Can-Fite BioPharma on 9 of the 17 factors compared between the two stocks.
Get Can-Fite BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Can-Fite BioPharma Competitors List
Related Companies and Tools
This page (NYSE:CANF) was last updated on 5/22/2025 by MarketBeat.com Staff
